Brief: Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab)

Mural Oncology

25/03/2025 11:49

March 25 (Reuters) - Mural Oncology PLC MURA.O:

MURAL ONCOLOGY PROVIDES UPDATE ON PHASE 3 ARTISTRY-7 TRIAL OF NEMVALEUKIN IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

MURAL ONCOLOGY PLC - TOPLINE RESULTS FOR ARTISTRY-6 TRIAL EXPECTED IN Q2 2025

MURAL ONCOLOGY PLC - NEMVALEUKIN HAS FAVORABLE SAFETY PROFILE IN OVER 800 PATIENTS

MURAL- BASED ON OVERALL SURVIVAL DATA OBSERVED IN INTERIM ANALYSIS IN PLATINUM-RESISTANT OVARIAN CANCER, TO NOT PROGRESS TRIAL TO FINAL ANALYSIS

Source text: ID:nGNX6TFw6g

Further company coverage: MURA.O

 ((Reuters.Briefs@thomsonreuters.com;))